{"symbol":"LLY","fiscalQuarter":"Q3-2023","reportDate":"2023-11-02","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2023","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Up 4.66%","keyNumbers":[{"metric":"EPS","actual":"$0.10","expected":"N/A","surprise":"+195.24%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering innovative treatments."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Eli Lilly's strong EPS performance, significantly exceeding expectations, led to a positive stock reaction, with shares rising by 4.66%. The company did not disclose revenue figures or future guidance, leaving some uncertainty. Investors may view the EPS beat as a sign of strong operational performance, but the lack of revenue data could raise questions about overall growth.","metaDescription":"Eli Lilly (LLY) Q3 2023 earnings: EPS beat expectations. Stock up 4.66%. Full breakdown."}}